BAK BRASKEM SA IFRS
Industrial Organic Chemicals · NYSE · SEC CIK 1071438 · Reporting currency BRL · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-26.9%
TTM net income YoY-1,262.8%
TTM EPS YoY—
Revenue 3-yr CAGR6.4%
Net income 3-yr CAGR—
Margins
Gross margin4.3%
Operating margin-4.0%
Net margin-6.5%
FCF margin-9.6%
EBITDA margin3.4%
Returns
ROE-80.9%
ROA-5.1%
ROIC (approx.)-5.5%
Asset turnover0.79x
Leverage & solvency
Liabilities / assets96.4%
Debt / equity12.70x
Current ratio1.53x
Interest coverage-0.50x
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue6.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: BRL | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 77.41B | 70.57B | 96.52B | 105.62B | 58.54B |
| Cost of revenue | 71.41B | 67.55B | 85.16B | 73.57B | 47.33B |
| Gross profit | 6.00B | 3.02B | 11.36B | 32.06B | 11.21B |
| R&D expense | 463.00M | 383.00M | 374.00M | 297.00M | 250.65M |
| SG&A expense | 2.64B | 2.47B | 2.76B | 2.52B | -4.08B |
| Operating income | -1.08B | -2.79B | 4.27B | 26.04B | -71.89M |
| Interest expense | 6.85B | 5.59B | 5.07B | 4.90B | 4.91B |
| Pretax income | -17.73B | -6.19B | 47.00M | 17.96B | -9.68B |
| Income tax | -5.68B | -1.30B | 868.00M | 4.00B | -2.67B |
| Net income | -11.32B | -4.58B | -336.00M | 13.98B | -6.69B |
| EBITDA | 3.87B | 2.41B | 9.01B | 30.22B | 3.98B |
| EPS (basic) | — | — | — | 17.57 | -8.41 |
| EPS (diluted) | — | — | — | 17.57 | -8.41 |
| Balance sheet | |||||
| Cash & equivalents | 14.99B | 14.19B | 12.47B | 8.68B | 13.86B |
| Short-term investments | 1.79B | 4.96B | 2.29B | 3.49B | 3.63B |
| Receivables | 3.56B | 2.91B | 3.23B | 7.15B | 4.73B |
| Inventory | 13.69B | 12.53B | 14.03B | 16.34B | 8.38B |
| Current assets | 37.04B | 37.44B | 34.46B | 39.29B | 34.19B |
| PP&E, netmay include right-of-use assets (IFRS) | 40.42B | 38.41B | 37.76B | 37.22B | 35.93B |
| Intangibles | — | — | — | 2.88B | 2.83B |
| Total assets | 101.58B | 91.74B | 88.05B | 92.56B | 86.08B |
| Current liabilities | 28.27B | 24.49B | 24.19B | 25.19B | 28.39B |
| Short-term debt | 14.28B | 10.51B | 10.50B | 12.22B | 4.40B |
| Long-term debt | 50.95B | 40.21B | 34.33B | 33.55B | 40.41B |
| Total debt | 65.23B | 50.72B | 44.84B | 45.78B | 44.81B |
| Total liabilities | 105.85B | 88.46B | 3.01B | 4.19B | 89.95B |
| Shareholders' equity | -4.78B | 3.99B | 7.32B | 7.87B | -2.20B |
| Net debt | 50.24B | 36.53B | 32.37B | 37.10B | 30.95B |
| Shares outstanding | 797.21M | 797.21M | 797.21M | 797.21M | 797.22M |
| Cash flow statement | |||||
| Operating cash flow | 2.44B | -2.27B | 8.95B | 14.79B | 6.29B |
| Capital expenditure | 3.76B | 4.53B | 4.85B | 3.42B | 2.76B |
| Free cash flow | -1.33B | -6.80B | 4.10B | 11.37B | 3.53B |
| Investing cash flow | -3.48B | -4.53B | -4.95B | -3.38B | -2.72B |
| Financing cash flow | 469.00M | 8.87B | 225.00M | -16.97B | 2.17B |
| Depreciation & amortization | 4.95B | 5.21B | 4.73B | 4.18B | 4.05B |
| Dividends paid | 6.00M | 7.00M | 1.35B | 5.99B | 2.38M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, BRL, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.